Small Volume Injectable Market Scope
Injectables or small-volume parenteral solutions (SVPs) are solutions having a volume of less than 100 mL (as specified by USP) that are designed for intermittent intravenous delivery (usually defined as an infusion time not lasting longer than 6-8 hours). Powdered medications are packaged in vials and must be constituted (dissolved in a suitable liquid) before being used in a solution. SVPs in the form of ampules, vials, or prefilled syringes are usually added to a minibag or an LVP, but they can also be used as the final container. A solution to which such an additive has been added to a minibag or LVP is referred to as an admixture. SVPs are the backbone of basic IV compounding for hundreds of medicines that require additional dilution. Hospitals, healthcare systems, and ambulatory care infusion facilities continue to experience intermittent shortages of small-volume parenteral solutions (SVPs).
The Small Volume Injectable market study is segmented, by Application (Local Anesthetics, Vaccines and Others) and major geographies with country level break-up.
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA estimates that United States & German Players will contribute to the maximum growth of Global Small Volume Injectable market throughout the predicted period.
Allergan Inc. (Ireland), GlaxoSmithKline plc (United Kingdom), Johnson & Johnson (United States), Bayer AG (Germany), Teva Pharmaceuticals (Israel), Pfizer Inc. (United States), Becton, Dickinson and Company (United States), Eli Lilly and Company (United States), Novartis AG (Switzerland) and Baxter International, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Schott AG (Germany), Gerresheimer (Germany), Ypsomed (Switzerland) and B. Braun Melsungen (Germany).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AMA Research has segmented the market of Global Small Volume Injectable market by Type, Application and Region.
On the basis of geography, the market of Small Volume Injectable has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
On 4th May, 2020 - Tolmar Pharmaceuticals, Inc Received U.S. Food and Drug Administration (FDA) Approval to its New Drug Application for FENSOLVI (leuprolide acetate) For Injectable Suspension for The Treatment of Pediatric Patients Two Years of Age and Older with Central Precocious Puberty (CPP). and On 12th May, 2021 - Dr. Reddy's Laboratories Launched Ertapenem for Injection in the U.S. Market. The New Injection, 1 g/vial, is a Therapeutically Equivalent Generic Version of INVANZ (Ertapenem for Injection), 1 G/Vial, Approved by The US Food and Drug Administration (USFDA).
- Rising Geriatric Population
- Prevalence of Chronic Infectious Diseases
- High Investment in Health Care R&D
- Growing Healthcare Infrastructure Across Emerging Regions
- Lack of Skilled Professionals
- High Initial Investment
- Fierce Competitive Pressure
Key Target AudienceSmall Volume Injectable Manufactures, New Entrants and Investors, Small Volume Injectable Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
Frequently Asked Questions (FAQ):
1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
2. How big is the Small Volume Injectable Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.